Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Argus Health
Colorcon
Fish and Richardson
Chinese Patent Office
Harvard Business School
Johnson and Johnson
Covington

Generated: July 19, 2018

DrugPatentWatch Database Preview

Oritavancin diphosphate - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for oritavancin diphosphate and what is the scope of oritavancin diphosphate freedom to operate?

Oritavancin diphosphate
is the generic ingredient in one branded drug marketed by Melinta Therap and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oritavancin diphosphate has thirty-five patent family members in sixteen countries.

Two suppliers are listed for this compound.
Summary for oritavancin diphosphate
International Patents:35
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 20
Clinical Trials: 3
Patent Applications: 8
DailyMed Link:oritavancin diphosphate at DailyMed
Synonyms for oritavancin diphosphate
(4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin
(4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin phosphate(1:2)
(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin phosphate(1:2) (salt)
(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin
(4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)' -(p-(p-chlorophenyl)benzyl)vancomycin
(4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)'-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin phosphate (1:2) (salt)
(4'R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(sup 3)'-(p-(p-chlorophenyl)benzyl)vancomycin phosphate (1:2) (salt)
171099-57-3
192564-14-0
AKOS030526689
AKOS032944863
C12034
CHEBI:82699
CHEBI:83305
CHEMBL1688530
CHEMBL2105352
Chlorobiphenyl-chloroeremomycin
CS-5054
D05271
DB04911
HY-B1831A
LY 333328
LY 333328 diphosphate
LY-333328
LY333328
LY333328 diphosphate
NIQCDURSAMXDNX-OTLIHLCASA-N
Orbactiv
Orbactiv (TN)
Oritavancin
Oritavancin (diphosphate)
Oritavancin [INN]
oritavancin bisphosphate
Oritavancin diphosphate (USAN)
Oritavancin diphosphate [USAN]
oritavancin phosphate
PUG62FRZ2E
PWTROOMOPLCZHB-BHYQHFGMSA-N
SCHEMBL9947049
UNII-PUG62FRZ2E
UNII-VL1P93MKZN
VHFGEBVPHAGQPI-LXKZPTCJSA-N
VL1P93MKZN

US Patents and Regulatory Information for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for oritavancin diphosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Sign Up ➤ Sign Up
Melinta Therap ORBACTIV oritavancin diphosphate POWDER;IV (INFUSION) 206334-001 Aug 6, 2014 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for oritavancin diphosphate

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016000075 Germany ➤ Sign Up PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319
2016 00044 Denmark ➤ Sign Up PRODUCT NAME: ORITAVANCIN OG/ELLER FARMACEUTISKE SALTE HERAF, HERUNDER DIFOSFATSALTE; REG. NO/DATE: EU/1/15/989 20150323
/2016 Austria ➤ Sign Up PRODUCT NAME: ORITAVANCIN UND DESSEN PHARMAZEUTISCHE SALZE; REGISTRATION NO/DATE: EU/1/15/989 (MITTEILUNG) 20150323
90041-7 Sweden ➤ Sign Up PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Accenture
Mallinckrodt
Julphar
Medtronic
AstraZeneca
UBS
Cerilliant
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.